Search Results - "Elbezanti, Weam"

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma by Al-Odat, Omar S., von Suskil, Max, Chitren, Robert J., Elbezanti, Weam O., Srivastava, Sandeep K., Budak-Alpddogan, Tulin, Jonnalagadda, Subash C., Aggarwal, Bharat B., Pandey, Manoj

“…Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical…”
Get full text

Real-time visualization of chromatin modification in isolated nuclei by Sardo, Luca, Lin, Angel, Khakhina, Svetlana, Beckman, Lucas, Ricon, Luis, Elbezanti, Weam, Jaison, Tara, Vishwasrao, Harshad, Shroff, Hari, Janetopoulos, Christopher, Klase, Zachary A

“…Chromatin modification is traditionally assessed in biochemical assays that provide average measurements of static events given that the analysis requires…”
Get full text

Benzodiazepines Drive Alteration of Chromatin at the Integrated HIV-1 LTR by Elbezanti, Weam, Lin, Angel, Schirling, Alexis, Jackson, Alexandria, Marshall, Matthew, Duyne, Rachel Van, Maldarelli, Frank, Sardo, Luca, Klase, Zachary

“…Antiretroviral therapy (ART) lowers human immunodeficiency virus type 1 (HIV-1) viral load to undetectable levels, but does not eliminate the latent reservoir…”
Get full text

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment by Elbezanti, Weam Othman, Challagundla, Kishore B, Jonnalagadda, Subash C, Budak-Alpdogan, Tulin, Pandey, Manoj K

“…Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of…”
Get full text

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis by Al-Odat, Omar S, Elbezanti, Weam Othman, Gowda, Krishne, Srivastava, Sandeep K, Amin, Shantu G, Jonnalagadda, Subash C, Budak-Alpdogan, Tulin, Pandey, Manoj K

“…Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the…”
Get full text

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma by Von Suskil, Max, Sultana, Kazi Nasrin, Elbezanti, Weam Othman, Al-Odat, Omar S., Chitren, Robert, Tiwari, Amit K., Challagundla, Kishore B., Srivastava, Sandeep Kumar, Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K.

“…Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune…”
Get full text

Alprazolam Prompts HIV-1 Transcriptional Reactivation and Enhances CTL Response Through RUNX1 Inhibition and STAT5 Activation by Lin, Angel, Elbezanti, Weam Othman, Schirling, Alexis, Ahmed, Adel, Van Duyne, Rachel, Cocklin, Simon, Klase, Zachary

“…The HIV-1 pandemic is a significant challenge to the field of medicine. Despite advancements in antiretroviral (ART) development, 38 million people worldwide…”
Get full text

Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells by Elbezanti, Weam Othman, Al-Odat, Omar S, Chitren, Robert, Singh, Jaikee Kumar, Srivastava, Sandeep Kumar, Gowda, Krishne, Amin, Shantu, Robertson, Gavin P, Nemmara, Venkatesh V, Jonnalagadda, Subash C, Budak-Alpdogan, Tulin, Pandey, Manoj K

“…Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for…”
Get full text

Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells by Bhowmick, Kuntal, von Suskil, Max, Al-Odat, Omar S., Elbezanti, Weam Othman, Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K.

“…Multiple Myeloma (MM) is a malignant expansion of plasma cells in the bone marrow (BM), resulting in a disease characterized by symptoms of end organ damage…”
Get full text

1120 PROMISING POTENTIAL FOR MITHRAMYCIN A, A NOVEL EPIGENETIC ANTINEOPLASTIC AGENT, IN CYTOREDUCTIVE SURGERY FOR PERITONEAL COLORECTAL CANCER by Ghanem, Yazid K., Moccia, Matthew C., Saleh, Zena, Joshi, Hansa, Elbezanti, Weam, Hong, Young K.

Get full text

A Novel BTK Inhibitor Induces Cells Death and Enhances the Efficacies of Venetoclax in Acute Myeloid Leukemia Cells by Schmalbach, Nicole K, Al-Odat, Omar S, Elbezanti, Weam, Yao, Gabriella, Guirguis, Daniel A, Gowda, Krishne, Amin, Shantu G, Budak-Alpdogan, Tulin, Jonnalagadda, Subash C, Pandey, Manoj Kumar

Get full text

Abstract 4477: The development of a small molecule dual inhibitor of CXCR4 and Mcl-1 to target bortezomib resistant and stem-like cells in multiple myeloma by Elbezanti, Weam Othman, Al-Odat, Omar S., Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K.

“…Abstract Multiple myeloma (MM) is a malignant plasma-cell illness defined by clonal growth of malignant plasma cells within the bone marrow (BM)…”
Get full text

The inhibition of microRNAs by HIV-1 Tat suppresses beta catenin activity in astrocytes by Sardo, Luca, Vakil, Priyal R, Elbezanti, Weam, El-Sayed, Anas, Klase, Zachary

“…Long term infection with HIV-1, even in the context of therapy, leads to chronic health problems including an array of neurocognitive dysfunctions. The viral…”
Get full text

Abstract 3842: Neuroendocrine differentiation and treatment of human SCLC: NRF2 has a role by Hamad, Samera, Joshi, Hansa, Li, Yahui, Toma, Helen, Bendjilali, Nasrine, Jefferys, Stuart, Corcoran, David, Elbezanti, Weam, Major, Ben, Bernard, Weissman, Spitz, Francis

“…Abstract SCLC is a lethal form of lung cancer and highly metastatic disease with limited therapeutic options. Four main neuro and non-neuroendocrine SCLC…”
Get full text

Caveolin-1 Mediates Inflammatory Breast Cancer Cell Invasion via the Akt1 Pathway and RhoC GTPase by Joglekar, Madhura, Elbazanti, Weam O., Weitzman, Matthew D., Lehman, Heather L., van Golen, Kenneth L.

“…ABSTRACT With a propensity to invade the dermal lymphatic vessels of the skin overlying the breast and readily metastasize, inflammatory breast cancer (IBC) is…”
Get full text

Abstract A01: Development of a novel BTK inhibitor against resistant acute myeloid leukemia by Schmalbach, Nicole K., Al-Odat, Omar S., Elbezanti, Weam Othman, Yao, Gabriella, Guirguis, Daniel A., Gowda, Krishne, Amin, Shantu G, Budak-Alpdogan, Tulin, Jonnalagadda, Subash C., Pandey, Manoj K.

“…Abstract Acute myeloid leukemia (AML) is the most common leukemia in adult patients, with a 5-year survival rate of less than 30 percent. Therefore, more…”
Get full text

The Effect of Mutating RUNX1 Binding Site on HIV-1 Replication and Novel HIV-1 Latency Reversal through Using Clinically Prescribed Benzodiazepines by Elbezanti, Weam Othman

“…The major barrier to curing HIV-1 infection is latency. HIV-1 latent cells are those in which the viral genome has been integrated into the host cell genome…”
Get full text